Study on the Effect of Telerehabilitation Using Wearable Devices After ACL Reconstruction
Launched by PEKING UNIVERSITY THIRD HOSPITAL · Mar 17, 2024
Trial Information
Current as of July 24, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating a new way to help patients recover after surgery to repair an injured anterior cruciate ligament (ACL), which is a key ligament in the knee. The study is comparing traditional in-person rehabilitation, where patients see a therapist twice a week, to a remote rehabilitation program that uses wearable devices and an app for guidance. The goal is to see if using technology for recovery can be as safe and effective as the usual face-to-face therapy.
To participate, you need to be an adult between 18 and 65 years old who has had surgery for a single ACL injury and has access to a smartphone or tablet. You should also be able to use mobile apps and communicate in Mandarin. If you join the trial, you’ll receive care and support just like everyone else, but your rehabilitation will be guided remotely if you are in the remote group. All participants will check in with doctors before surgery and again at 3 and 6 months after surgery to monitor progress. This study is currently recruiting participants, so if you or someone you know fits the criteria, it could be a great opportunity to explore a new approach to recovery.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Adults (18-65 years old) with unilateral initial ACL rupture;
- • 2. have a mobile device (e.g., smartphone or tablet) that can connect to the Internet;
- • 3. be able to use mobile applications;
- • 4. be able to complete the plan and related follow-up three weeks before admission or within 3 months after discharge;
- • 5. be able to communicate with researchers in Chinese (Mandarin);
- • 6. Ability to provide informed and valid consent to participate in the study
- Exclusion Criteria:
- • 1. Undergoing revision and bilateral surgery;
- • 2. concomitant health conditions that are likely to interfere with rehabilitation exercises, such as severe visual impairment or blindness; Grade II or above heart failure according to the New York Heart Association;
- • 3. Have undergone other lower extremity surgery within the last 6 months or will undergo lower extremity surgery again within 3 months;
- • 4. Structural injuries such as collateral ligament and posterior cruciate ligament in the knee joint;
- • 5. Combined with knee joint infection, fracture, tumor, etc.;
- • 6. There are serious postoperative complications, such as incision infection, venous thromboembolism, etc.
- • 7. Acute surgery
About Peking University Third Hospital
Peking University Third Hospital is a leading medical institution in China, renowned for its commitment to advanced healthcare, innovative research, and comprehensive clinical services. As a prominent sponsor of clinical trials, the hospital emphasizes the integration of cutting-edge scientific research with patient-centered care to enhance therapeutic outcomes. With a multidisciplinary approach, the institution fosters collaboration among top-tier medical professionals and researchers, striving to contribute to the global medical community through rigorous clinical studies that address pressing health challenges. Its dedication to ethical standards and regulatory compliance ensures the safety and efficacy of new treatments, ultimately aiming to improve patient care and outcomes on both a national and international scale.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, Beijing, China
Patients applied
Trial Officials
quan J Wang, M.D.
Study Chair
Peking University Third Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported